Clinical trial
"An Open Safety Study and Description of the Parameters of the Therapeutic Efficacy of the Drug for Early Etiotropic Therapy for Coronavirus Infection Caused by the SARS-CoV-2 Virus, With a Single Application in Patients With Confirmed COVID-19 Diagnosis"
NCT05729360 is registered in ClinicalTrials.gov with Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- "An Open Safety Study and Description of the Parameters of the Therapeutic Efficacy of the Drug for Early Etiotropic Therapy for Coronavirus Infection Caused by the SARS-CoV-2 Virus, With a Single Application in Patients With Confirmed COVID-19 Diagnosis"
- Lead sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- March 31, 2023
- Completion date
- December 31, 2023
- Enrollment
- 30 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.